Canada’s access to new medicines is being pulled into an American drug-pricing fight. New reporting indicates that pharmaceutical companies have attributed 48 planned Canadian medicine launches—16 cancellations and 32 delays—to U.S. President Donald Trump’s most-favoured-nation drug-pricing policy, raising concerns that efforts to lower prescription costs in the United States could have unintended consequences north of the border.
The issue reaches beyond pharmaceutical balance sheets. For patients waiting for treatments for rare diseases, cancer, kidney conditions and other serious illnesses, a commercial decision to launch six months later—or not at all—can determine whether a promising therapy is realistically accessible. At the same time, Canada must protect public drug plans from unsustainable prices. The emerging dispute is therefore becoming a difficult test of how a smaller pharmaceutical market preserves both affordability and timely access when U.S. pricing policy changes the global calculation.
The 48-Launch Warning Comes From Pharmaceutical Companies
The headline figure comes from an EY survey of 31 pharmaceutical and life-sciences companies reported by CityNews on August 17, 2026. According to that reporting, companies said 16 medicine launches in Canada had been cancelled directly because of most-favoured-nation pricing, while another 32 had been delayed, bringing the total to 48. CityNews reported that the affected products include medicines that could extend, improve or save lives, and that some had already received Health Canada approval. The findings give a concrete number to a risk Canadian health-policy experts had been discussing since Trump revived international reference pricing in 2025: companies may become reluctant to establish a comparatively low price in a smaller market if that price could influence what they earn in the much larger United States.
There is an important qualification. The 48 figure is based on companies reporting their own launch decisions; it is not a government tally establishing causation product by product. CityNews did not publish a complete list identifying all 48 medicines, and individual launch decisions can involve reimbursement prospects, regulatory timing, commercial demand and other considerations. That does not make the result insignificant. A survey covering 31 industry participants provides an unusually direct look at how executives say U.S. policy is changing their behaviour. But describing the launches as industry-attributed to MFN pricing, rather than independently proven consequences in every case, provides a more accurate picture of the available evidence.
How Trump’s Most-Favoured-Nation Policy Changes the Equation
Trump signed Executive Order 14297 on May 12, 2025, directing his administration to bring American prescription-drug prices closer to those paid in comparable developed countries. Eight days later, the U.S. Department of Health and Human Services provided a more specific benchmark: for affected brand-name drugs without generic or biosimilar competition, manufacturers were expected to align U.S. prices with the lowest price found in an OECD country whose GDP per capita was at least 60% of the U.S. level. The administration argued that American patients had long paid disproportionately high prices while manufacturers accepted substantially lower prices abroad. U.S. government research confirms the underlying price gap is large: using 2022 data, American prices across brand-name and generic drugs were about 2.78 times those in comparison countries.
The administration subsequently moved beyond the original executive order. By April 23, 2026, the White House said it had reached MFN agreements with all 17 major pharmaceutical manufacturers it had initially targeted, companies it said represented 86% of the branded-drug market. Those agreements vary in detail, but the broader direction is unmistakable: the United States is using its enormous purchasing power to push American prices toward international benchmarks while simultaneously pressuring manufacturers to rebalance prices across countries. That creates a new incentive for global drugmakers. If launching a medicine at a lower price in Canada risks weakening the price available in the U.S., delaying the Canadian launch can become financially attractive even when the medicine itself has already cleared scientific or regulatory hurdles.
Why Canada Can Become a Risky Launch Market
The concern is rooted in the extraordinary size and profitability of the U.S. pharmaceutical market. When a company evaluates where to introduce a new patented medicine, it is not simply deciding whether sales in Canada will be profitable. It must consider whether the Canadian price could affect revenues elsewhere. The C.D. Howe Institute warned shortly after Trump’s 2025 executive order that international reference pricing could give manufacturers a significant incentive to delay launches in markets where prices might undermine higher U.S. returns. One possible response is to seek higher prices outside the United States. Another is to postpone entry until the company has secured the U.S. pricing position it wants. A third is to avoid certain smaller markets altogether.
Yet describing Canada merely as a low-price pharmaceutical market is misleading. The Patented Medicine Prices Review Board found that Canadian list prices for patented medicines were the fifth-highest among 31 OECD countries in 2024 and higher, on average, than those in every country in the PMPRB’s 11-country comparator group. The complication is that public and private insurers frequently negotiate confidential discounts, meaning published list prices are not necessarily the true amounts ultimately paid. That distinction matters enormously under international reference pricing. If U.S. policy makes foreign prices more consequential, manufacturers have stronger reasons to protect the pricing information that can be observed—or to reconsider when and where a product is introduced.
Vanrafia Shows the Gap Between Drug Approval and Patient Access
A recent kidney-disease treatment illustrates how authorization alone does not guarantee broad access. Health Canada approved Novartis’s Vanrafia, or atrasentan, in July 2026 for reducing proteinuria in adults with primary immunoglobulin A nephropathy, known as IgAN, who are at risk of rapid disease progression. IgAN is an autoimmune kidney disease in which deposits build up in the kidneys, causing inflammation and damage. Novartis said the approval was supported by its Phase III ALIGN study, where the medicine produced a statistically significant reduction in a measure of urinary protein compared with placebo. For patients living with a progressive kidney disease, regulatory approval would normally represent an important step toward another treatment option.
But Novartis subsequently told CityNews that it would not seek public reimbursement for Vanrafia in Canada at this time, saying the likelihood of successfully obtaining reimbursement under the current Canadian access environment was limited. Crucially, the company did not identify Trump’s MFN policy as the reason for that particular decision. Vanrafia therefore should not be presented as a proven example among the 48 MFN-related cancellations and delays. Its relevance is different: it demonstrates how a medicine can pass Health Canada’s safety, efficacy and quality review but still fail to advance through the reimbursement pathway needed for broad public access. For patients, the distinction between “approved in Canada” and “accessible in Canada” can be substantial.
Canada’s Reimbursement System Was Already Complicated
After Health Canada authorizes a new medicine, the journey toward public coverage can involve several additional stages. Canada’s Drug Agency conducts health-technology assessments for most jurisdictions, while Quebec uses INESSS. A positive reimbursement recommendation can then lead to negotiations between the manufacturer and the pan-Canadian Pharmaceutical Alliance, which negotiates on behalf of participating public drug plans. Under the pCPA’s standard process, it aims to complete a negotiation within 90 business days after a formal letter of engagement, though negotiations can be paused or extended. Even after an agreement is reached, individual public drug plans must translate the negotiated terms into their own listing agreements and make coverage decisions according to their respective processes.
A federal pharmaceutical and life-sciences task force highlighted the accumulated effect in July 2026. Its report estimated that health-technology assessment can take about 200 days, price negotiation about 195 days, and provincial or territorial listing decisions roughly 99 to 219 days, although processes increasingly overlap rather than occurring entirely one after another. Those reviews exist for a reason: governments have finite health budgets and need evidence that a treatment’s benefits justify its cost. The dilemma is that an already complex system becomes more vulnerable when manufacturers suddenly have another reason to delay participation. Trump’s policy did not create Canada’s reimbursement bottlenecks, but it may make those bottlenecks more consequential when companies decide which countries deserve priority.
Research Shows the Pricing-and-Launch Link Is Not Simple
There is evidence that medicine launches in Canada have slowed, but previous research cautions against attributing every change to pricing policy. A peer-reviewed 2024 study published in the Canadian Medical Association Journal examined new patented medicines across Canada and international comparator countries. Among the molecules studied, the share launched in Canada within two years of their first global introduction fell from 45.0% before the period of regulatory uncertainty to 30.8% during 2018–2021. At first glance, that seems to support the argument that tougher or uncertain Canadian pricing rules discouraged launches. The researchers, however, found similar changes across comparator countries and concluded there was no overall negative launch effect attributable to uncertainty around Canada’s PMPRB reforms, with an important exception involving medicines offering major therapeutic benefit.
That finding does not disprove the new MFN concern. It shows why causation must be examined carefully. The current situation is different because the incentive is originating in the United States and can directly link a company’s earnings in its largest market to prices established elsewhere. The EY findings provide contemporaneous evidence that companies themselves say MFN is altering Canadian decisions, while the earlier academic research demonstrates that launch behaviour can also change for unrelated market and regulatory reasons. Taken together, the evidence supports monitoring individual products, submission dates and reimbursement decisions rather than assuming either that MFN has no effect or that every missing Canadian launch can be laid at Washington’s door.
Switzerland Is Seeing a Similar Warning Sign
Canada is not alone in confronting this problem. On August 13, Reuters reported that pharmaceutical companies were holding back reimbursement applications in Switzerland because of concern over how Swiss prices might affect U.S. pricing under Trump’s approach. An Interpharma industry study found that, among 22 innovative medicines introduced between January 2025 and June 2026, seven were not submitted for inclusion in Switzerland’s mandatory health-insurance reimbursement system. Another three were not submitted for Swiss market approval at all, which the industry group also attributed to the U.S. policy. Only 15 medicines were submitted for reimbursement during the 18-month period, compared with an average of 24 in comparable periods between 2019 and 2025.
As in Canada, those numbers originate from pharmaceutical-industry research and should be interpreted accordingly. Still, seeing similar behaviour reported in two sophisticated pharmaceutical markets makes the mechanism harder to dismiss as a uniquely Canadian dispute. Switzerland is particularly relevant because reimbursement establishes prices that can matter for international comparisons. If companies conclude that an early launch in a smaller country can lower the benchmark applied to their American business, the logical commercial response may be to sequence launches differently. For patients, that corporate sequencing decision can translate into months or years of additional waiting.
Ottawa Now Has to Balance Affordability Against Access
The federal government was already attempting to modernize the pharmaceutical system before the latest 48-launch warning. A federal task force established in March 2026 produced 39 recommendations addressing medicine access, affordability, supply security, regulation, research and commercialization. Among other proposals, it recommended closer coordination among Health Canada, Canada’s Drug Agency and the pCPA and urged policymakers to examine pricing frameworks in light of the changing geopolitical environment. The government said on July 24 that it would carefully consider the recommendations. Separately, Health Canada introduced a Ministerial Reliance Order designed to reduce unnecessary duplication by allowing Canadian reviewers to use certain work completed by trusted foreign regulators. Health Canada said it had authorized 537 new drugs and medical devices during the three months preceding its July announcement.
Those reforms may make Canada a faster and more attractive launch destination, but they cannot eliminate the core economic tension created by U.S. reference pricing. Simply paying substantially more for every new medicine would undermine the bargaining systems designed to protect taxpayers, employers and patients from excessive costs. Refusing to adjust anything, however, could become increasingly risky if global companies place Canada further down their launch lists. A durable response will likely require better coordination, faster reimbursement decisions, careful monitoring of launches that disappear from the Canadian pipeline, and a clear distinction between reasonable cost containment and barriers that make entry commercially unattractive. The 48 delayed or cancelled launches are best viewed as an early warning: a U.S. policy intended to make medicines cheaper for Americans may be changing when Canadians get access to them—and, in some cases, whether they get access at all.
